Physician profile
Mark O Carter
NPI 1831125806
$7,774.97
in general payments reported to CMS, 2019-2025
56 companies · $961 in 2025
The $961 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,953 · 2020: $724 · 2021: $1,170 · 2022: $772 · 2023: $1,137 · 2024: $1,057 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,155.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,218.23 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $656.90 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $564.30 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $441.21 | 2019-2025 | |
| Lilly USA, LLC | $415.44 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $402.61 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.87 | 2019-2025 | Synjardy, Tradjenta, Jardiance |
| Allergan, INC. | $292.11 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $248.82 | 2021-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $237.49 | 2019-2023 | Dificid |
| Glaxosmithkline, LLC. | $216.15 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Corium, LLC | $202.49 | 2022-2025 | Azstarys, Adlarity |
| Exact Sciences Corporation | $191.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $168.31 | 2020-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $154.39 | 2019-2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.